351 related articles for article (PubMed ID: 24388026)
1. Biomedical system dynamics to improve anemia control with darbepoetin alfa in long-term hemodialysis patients.
McCarthy JT; Hocum CL; Albright RC; Rogers J; Gallaher EJ; Steensma DP; Gudgell SF; Bergstralh EJ; Dillon JC; Hickson LJ; Williams AW; Dingli D
Mayo Clin Proc; 2014 Jan; 89(1):87-94. PubMed ID: 24388026
[TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
3. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
[TBL] [Abstract][Full Text] [Related]
4. Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience.
Agrawal V; Mukherjee S; Kosuri R; Dumler F
Am J Ther; 2010; 17(5):469-75. PubMed ID: 19770634
[TBL] [Abstract][Full Text] [Related]
5. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
6. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
[TBL] [Abstract][Full Text] [Related]
7. Association of a change in erythropoiesis-stimulating agent dose during hospitalization and subsequent hemoglobin levels and transfusions in hemodialysis patients.
Wong BC; Ravani P; Manns BJ; Lewin A; Zhang X; Chin R; Hemmelgarn BR; Tonelli M; Oliver MJ; Quinn RR
Am J Kidney Dis; 2013 Nov; 62(5):947-52. PubMed ID: 23856380
[TBL] [Abstract][Full Text] [Related]
8. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population.
Sharma A; Yee J; Gandra SR; Khan I; Petersen J
Curr Med Res Opin; 2010 Nov; 26(11):2679-87. PubMed ID: 20942616
[TBL] [Abstract][Full Text] [Related]
9. Perihospitalization patterns of hemoglobin levels and erythropoiesis-stimulating agent doses in US hemodialysis patients, 1998-2009.
Foley RN; Solid CA; Lamb K
Hemodial Int; 2014 Jan; 18(1):24-31. PubMed ID: 24131588
[TBL] [Abstract][Full Text] [Related]
10. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis.
Macdougall IC; Provenzano R; Sharma A; Spinowitz BS; Schmidt RJ; Pergola PE; Zabaneh RI; Tong-Starksen S; Mayo MR; Tang H; Polu KR; Duliege AM; Fishbane S;
N Engl J Med; 2013 Jan; 368(4):320-32. PubMed ID: 23343062
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
Solomon SD; Uno H; Lewis EF; Eckardt KU; Lin J; Burdmann EA; de Zeeuw D; Ivanovich P; Levey AS; Parfrey P; Remuzzi G; Singh AK; Toto R; Huang F; Rossert J; McMurray JJ; Pfeffer MA;
N Engl J Med; 2010 Sep; 363(12):1146-55. PubMed ID: 20843249
[TBL] [Abstract][Full Text] [Related]
12. Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.
Fuller DS; Robinson BM; Locatelli F; Pisoni RL
Nephron; 2018; 140(1):24-30. PubMed ID: 29945128
[TBL] [Abstract][Full Text] [Related]
13. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Yoshida T; Hayashi M
Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
[TBL] [Abstract][Full Text] [Related]
14. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
[TBL] [Abstract][Full Text] [Related]
15. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
[TBL] [Abstract][Full Text] [Related]
16. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
[TBL] [Abstract][Full Text] [Related]
17. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
[TBL] [Abstract][Full Text] [Related]
18. Darbepoetin use for the treatment of anemia in hemodialysis patients in Saudi Arabia.
Shaheen FA; Akeel N; Alfi A; Harbi A; Tarif N; Souqiyyeh MZ
Saudi J Kidney Dis Transpl; 2006 Sep; 17(3):365-72. PubMed ID: 16970257
[TBL] [Abstract][Full Text] [Related]
19. Effect of darbepoetin alfa on renal anemia in Japanese hemodialysis patients.
Kusaba T; Ishida R; Nakayama M; Kato H; Uchiyama H; Sato K; Mori Y; Matsubara H; Kajita Y
Arzneimittelforschung; 2009; 59(9):435-9. PubMed ID: 19856789
[TBL] [Abstract][Full Text] [Related]
20. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease.
Joy MS; Candiani C; Vaillancourt BA; Chin H; Hogan SL; Falk RJ
Pharmacotherapy; 2007 May; 27(5):734-44. PubMed ID: 17461709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
